Sethi Vidhu, Qin Li, Cox Eugène, Trocóniz Iñaki F, Della Pasqua Oscar
Medical Affairs, Haleon (Formerly GSK Consumer Healthcare), GSK Asia House, Rochester Park, Singapore, 139234, Singapore.
Quantitative Science, Certara, Princeton, USA.
Pain Ther. 2024 Feb;13(1):145-159. doi: 10.1007/s40122-023-00569-z. Epub 2024 Jan 6.
Acetaminophen and topical diclofenac (AtopD) have complementary mechanisms of action and are therefore candidates for combination use in osteoarthritis (OA) pain. However, an evidence gap exists on their combination use in OA pain. This study aimed to assess the effects of this combination and compare its performance relative to monotherapies on pain score reduction and opioid-sparing effect by leveraging evidence from acute pain setting using a model-based meta-analysis (MBMA).
A literature search was conducted using the MEDLINE database to identify randomized controlled trials (RCTs) studying the combination for acute pain. Subsequently, an MBMA of RCTs was implemented in conjunction with extrapolation principles to infer efficacy in the population of interest. Pain score reduction and opioid-sparing effect (OSE) were selected as the measures of efficacy.
A total of 11 RCTs encompassing 1396 patients were included. Exploratory evaluation revealed AtopD combination to show greater pain score reduction versus acetaminophen monotherapy. However, pain score reduction was more susceptible to confounding by opioid patient-controlled analgesia (PCA) than OSE. Therefore, a parsimonious MBMA evaluating OSE was developed from 5 of the 11 RCTs (n = 353 patients). The analysis revealed a statistically significant interaction coefficient, suggesting a reduction of 32% in opioid use with the combination versus acetaminophen monotherapy. Differences in the effect size of the combination were less conclusive versus diclofenac monotherapy.
Our results indicate greater pain reduction and opioid-sparing efficacy for the AtopD combination versus acetaminophen monotherapy. Given the similar pain pathways and mechanisms of action of the two drugs in acute and mild-to-moderate OA pain, comparable beneficial effects from the combination therapy may be anticipated following extrapolation to chronic OA pain. Prospective RCTs and real-world studies in OA pain are needed to confirm the differences in the efficacy of the combination treatment observed in our study.
对乙酰氨基酚和外用双氯芬酸(AtopD)具有互补的作用机制,因此是骨关节炎(OA)疼痛联合用药的候选药物。然而,关于它们在OA疼痛中的联合使用存在证据空白。本研究旨在评估这种联合用药的效果,并通过基于模型的荟萃分析(MBMA)利用急性疼痛背景下的证据,比较其相对于单一疗法在降低疼痛评分和减少阿片类药物用量方面的表现。
使用MEDLINE数据库进行文献检索,以识别研究该联合用药治疗急性疼痛的随机对照试验(RCT)。随后,结合外推原则对RCT进行MBMA,以推断在目标人群中的疗效。选择疼痛评分降低和阿片类药物节省效应(OSE)作为疗效指标。
共纳入11项RCT,涉及1396例患者。探索性评估显示,与对乙酰氨基酚单一疗法相比,AtopD联合用药在降低疼痛评分方面效果更佳。然而,与OSE相比,疼痛评分降低更容易受到阿片类药物患者自控镇痛(PCA)的混杂影响。因此,从11项RCT中的5项(n = 353例患者)开展了一项评估OSE的简约MBMA。分析显示存在统计学显著的交互系数,表明联合用药与对乙酰氨基酚单一疗法相比,阿片类药物用量减少了32%。与双氯芬酸单一疗法相比,联合用药效应大小的差异不太明确。
我们的结果表明,与对乙酰氨基酚单一疗法相比,AtopD联合用药在减轻疼痛和节省阿片类药物方面疗效更佳。鉴于这两种药物在急性和轻至中度OA疼痛中具有相似的疼痛途径和作用机制,推断联合疗法在慢性OA疼痛中可能具有类似的有益效果。需要开展OA疼痛的前瞻性RCT和真实世界研究,以证实我们研究中观察到的联合治疗疗效差异。